1. [Results of the clinical study of a new adrenergic beta blocker levobunolol hydrochloride in healthy subjects and in patients with glaucoma].
- Author
-
Egorov EA and Shmeleva IA
- Subjects
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Drug Evaluation, Female, Glaucoma physiopathology, Glaucoma, Angle-Closure drug therapy, Glaucoma, Angle-Closure physiopathology, Glaucoma, Neovascular physiopathology, Glaucoma, Open-Angle drug therapy, Glaucoma, Open-Angle physiopathology, Humans, Intraocular Pressure physiology, Levobunolol administration & dosage, Levobunolol therapeutic use, Male, Middle Aged, Reference Values, Time Factors, Glaucoma drug therapy, Glaucoma, Neovascular drug therapy, Intraocular Pressure drug effects, Levobunolol pharmacology
- Abstract
Effects of a single instillation of levobunolol, a new nonselective beta-adrenoblocker, in normal subjects and patients with various forms of glaucoma were under study, as were the effects of prolonged administration of this drug in patients with open-angle glaucoma. Short-term observations have revealed a hypotensive effect in all the examinees, the highest in patients with open-angle glaucoma (30.2%). Levobunolol did not influence the diameter of the pupil and accommodation, nor did it essentially change the cardiovascular activity. Prolonged administration of the drug resulted in a stable reduction of intraocular pressure by 20-30% in 70% of patients with open-angle glaucoma. Tonographic studies have shown that the drug reduced the intraocular fluid production and in case of a prolonged administration a trend to an elevation of the coefficient of the easiness of fluid discharge is observed.
- Published
- 1992